Stifel

Checkpoint Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 4, 2024 deadline.

Retrieved on: 
星期三, 四月 10, 2024
HireRight, Risk, Stifel, Employment, IPO, Defendant, CKPT, Checkpoint, Growth, Alpha, Cryptocurrency

LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) investors that a lawsuit was filed on behalf of investors that purchased Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”).

Key Points: 
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • On November 1, 2021, HireRight initiated its IPO, selling around 22 million shares of common stock at $19.00 per share.
  • Stifel also noted that a substantial portion of the company's growth stemmed from existing client hiring rather than new client acquisitions.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

HireRight Holdings Corporation investors: Please contact the Portnoy Law Firm to recover your losses; June 3, 2024 deadline

Retrieved on: 
星期三, 四月 10, 2024
HireRight, Risk, Stifel, Employment, Growth, HRT, IPO, Defendant, Alpha, Security (finance)

​LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) investors that a lawsuit was filed on behalf of investors that purchased HireRight securities pursuant and/or traceable to the Offering Documents issued in connection with HireRight’s October 2021 initial public offering (the “IPO” or “Offering”).

Key Points: 
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • On November 1, 2021, HireRight initiated its IPO, selling around 22 million shares of common stock at $19.00 per share.
  • Stifel also noted that a substantial portion of the company's growth stemmed from existing client hiring rather than new client acquisitions.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

Paystand Acquires Teampay for Giant Leap Toward B2B Payment Revolution

Retrieved on: 
星期四, 四月 25, 2024
Professional Services, Payments, Blockchain, Technology, Software, Fintech, Accounting, Decentralized finance, CFO, NetSuite, DSO, Economics, Stifel, Heart, AP, B2B, Microsoft, Acquisition, Sage, CFOS, Cryptocurrency

Paystand, the global leader in blockchain-enabled B2B payments, today announced the acquisition of Teampay, an industry-leading spend management software.

Key Points: 
  • Paystand, the global leader in blockchain-enabled B2B payments, today announced the acquisition of Teampay, an industry-leading spend management software.
  • The transaction creates a B2B payments powerhouse whose continued goal is to revolutionize payments by expanding the largest, fastest, and most cost-efficient B2B payments network.
  • The combined Paystand platform empowers CFOs to drive profitable behaviors among employees, vendors, and customers.
  • "This acquisition represents a pivotal moment not only for Paystand and Teampay but also for the entire B2B payments industry.

MSA Safety Welcomes Larry De Maria Executive Director, Investor Relations

Retrieved on: 
星期四, 四月 25, 2024
William Blair & Company, Safety, MSA, Research, Stifel, Prudential Securities, Sterne, Corporate development, MSA Safety, Senior, Acquisition, CFA, Research fellow, Management

PITTSBURGH, April 25, 2024 /PRNewswire/ -- MSA Safety, Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastructures, has named Larry De Maria, CFA, as its Executive Director, Investor Relations.

Key Points: 
  • PITTSBURGH, April 25, 2024 /PRNewswire/ -- MSA Safety, Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastructures, has named Larry De Maria, CFA, as its Executive Director, Investor Relations.
  • Mr. De Maria joins MSA Safety from William Blair & Company where he served as Group Head, Global Industrial Infrastructure, Equity Research.
  • "As a highly respected analyst who has followed MSA Safety for more than five years, Larry brings to this position an extensive understanding of our business and the investor landscape.
  • Chris Hepler, who has served as Executive Director of Corporate Development and Investor Relations since 2021, will now lead MSA's corporate development function.

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Retrieved on: 
星期三, 四月 10, 2024
Stifel, SNDX

WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m.

Key Points: 
  • WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m.
  • ET.
  • A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.

Revolution Medicines to Participate in Upcoming Investor Conferences

Retrieved on: 
星期四, 四月 4, 2024
Stifel, Patient, Webcast, Conference, Revolution

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.

Key Points: 
  • REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.
  • Details of the company’s participation are as follows:
    To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .
  • Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

Retrieved on: 
星期二, 四月 2, 2024
Stifel, Tiger, Sale, Berkeley Research Group, Acquisition, Blank Rome, United States bankruptcy court, Bankruptcy, Breast, Regenerative medicine, Hearing, Kirkland & Ellis, Kirkland, Insurance

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (“Sientra” or the “Company”) announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC (“Tiger”) has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consideration of $42.5 million as well as assume certain liabilities of the Company, including up to $7 million in cure costs for certain assumed contracts, all the Company’s warranties for breast implants sold prior to the closing date, and all of the Company’s customer contracts.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (“Sientra” or the “Company”) announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC (“Tiger”) has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business.
  • Sientra also announced that it has entered into a definitive agreement with Nuance Intermediary, LLC (“Nuance”), pursuant to which Nuance will acquire substantially all the assets of Sientra used in its BIOCORNEUM business.
  • Tiger Aesthetics Medical, LLC is represented by Blank Rome LLP as legal counsel and H.C. Wainwright & Co. as investment banker.
  • Nuance Intermediary, LLC, an investment of Nuance Holdings LLC, as well as the owner of Nuance Medical, is represented by Ferguson Braswell Fraser Kubasta PC as legal counsel.

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Retrieved on: 
星期四, 三月 28, 2024
Stifel, BB Biotech, Exchange, Sale, Cancer, Security (finance), Therapy

The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.

Key Points: 
  • The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.
  • The closing of the second tranche is subject to the satisfaction of customary closing conditions.
  • MTEM intends to use the net proceeds from the proceeds of the second tranche to fund its ongoing clinical studies, working capital and for general corporate purposes.
  • MTEM has agreed to file a resale registration statement with the Securities and Exchange Commission registering the resale of the securities issued in the second tranche.

CSI Customer Conference Returns With Keynote Speaker Tim Tebow

Retrieved on: 
星期二, 四月 9, 2024
Technology, Finance, Consulting, Banking, Professional Services, Other Philanthropy, Philanthropy, Other Technology, Software, Fund Raising, Internet, Fintech, Data Management, Security, Stifel, Speech, CSI, Intelligence, Tim Tebow, Perseverance, Education, Federal, Hawthorn, University, News, CX, Community service, Party, Housing, Heart, Federal Reserve, CMO, Friends

CSI , a leading provider of end-to-end financial software and technology, will hold its 2024 customer conference, titled CX24: Authentic Roots, Ambitious Pursuits, from April 14 to April 17 in San Antonio.

Key Points: 
  • CSI , a leading provider of end-to-end financial software and technology, will hold its 2024 customer conference, titled CX24: Authentic Roots, Ambitious Pursuits, from April 14 to April 17 in San Antonio.
  • David Culbertson, CSI’s president and CEO, will open the conference with his keynote speech, featuring the latest news from CSI, his vision for the company’s future and insight into today’s community banking industry.
  • “The integrity and authenticity of customer relationships are the heart of community banking—and the key to creating lifelong account holders.
  • For more information on the customer-only conference, including a list of breakout sessions, visit the CX24 website .

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
星期一, 四月 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.